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GSK-3β-induced Tau pathology drives hippocampal
neuronal cell death in Huntington’s disease:
involvement of astrocyte–neuron interactions
F L’Episcopo1,2,8, J Drouin-Ouellet3,8, C Tirolo1, A Pulvirenti4, R Giugno4, N Testa1, S Caniglia1, MF Serapide2, G Cisbani5, RA Barker3,6,
F Cicchetti5,7 and B Marchetti*,1,2
Glycogen synthase kinase-3β (GSK-3β) has emerged as a critical factor in several pathways involved in hippocampal neuronal
maintenance and function. In Huntington’s disease (HD), there are early hippocampal deficits both in patients and transgenic
mouse models, which prompted us to investigate whether disease-specific changes in GSK-3β expression may underlie these
abnormalities. Thirty-three postmortem hippocampal samples from HD patients (neuropathological grades 2–4) and age- and
sex-matched normal control cases were analyzed using real-time quantitative reverse transcription PCRs (qPCRs) and
immunohistochemistry. In vitro and in vivo studies looking at hippocampal pathology and GSK-3β were also undertaken in
transgenic R6/2 and wild-type mice. We identified a disease and stage-dependent upregulation of GSK-3βmRNA and protein levels
in the HD hippocampus, with the active isoform pGSK-3β-Tyr216 being strongly expressed in dentate gyrus (DG) neurons and
astrocytes at a time when phosphorylation of Tau at the AT8 epitope was also present in these same neurons. This upregulation of
pGSK-3β-Tyr216 was also found in the R6/2 hippocampus in vivo and linked to the increased vulnerability of primary hippocampal
neurons in vitro. In addition, the increased expression of GSK-3β in the astrocytes of R6/2 mice appeared to be the main driver of
Tau phosphorylation and caspase3 activation-induced neuronal death, at least in part via an exacerbated production of major
proinflammatory mediators. This stage-dependent overactivation of GSK-3β in HD-affected hippocampal neurons and astrocytes
therefore points to GSK-3β as being a critical factor in the pathological development of this condition. As such, therapeutic
targeting of this pathway may help ameliorate neuronal dysfunction in HD.
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Huntington’s disease (HD) is an autosomal-dominant neuro-
degenerative disorder of the CNS that is characterized
by progressive neurological deficits, including involuntary
movements (e.g., chorea, dystonia and gait abnormalities),
psychiatric disturbances and cognitive decline.1 Notably,
cognitive impairments appear early in the disease course
and profoundly impact on the patients’ quality of life.2,3 This
clinical profile reflects the fact that while the major pathology of
HD involves the striatum and deep layers of the cerebral
cortex,1,4–7 it is not restricted to this site but involves many
other areas of the CNS from disease onset, including the
hippocampus.8–10 Both neuronal loss in the hippocampal CA1
region and volumetric reduction on MRI have been reported
in patients,8–10 which are also seen in animal models of
the disease. All of this suggests that there is a selective
vulnerability of hippocampal neurons to the disease process
that may explain some of the cognitive and psychiatric deficits
commonly seen in HD.11
The genetic basis of HD involves a CAG repeat expansion in
exon 1 of the huntingtin (Htt) gene, leading to an abnormally
long polyglutamine (polyQ) tract in Htt, a protein widely
expressed throughout the brain and peripheral tissues.4,12
This mutant form of the huntingtin protein (mHtt) ultimately
forms aggregates in a variety of cell types with pathological
consequences impacting on a wide range of cellular pro-
cesses, all of which lead to neuronal dysfunction and
eventually cell loss.4–7 In astrocytes, the accumulation of
mHtt alters several fundamental glial properties that are critical
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for neuronal survival, and thus this cell may also indirectly
contribute to increase neuronal vulnerability and/or neuronal
cell death.13–18
Compelling evidence has been recently provided for the
existence of Tau-related pathology as a contributing factor to
the cognitive deficits seen in patients with HD. Postmortem
analysis of HD brains has revealed an increase both in total
Tau and its phosphorylated form, as well as its accumulation
within mHtt-positive inclusions,19 including in the hippocam-
pus. Two independent reports followed demonstrating cortical
Tau hyperphosphorylation in the R6/2 transgenic (TG) mouse
model of HD.20,21 Furthermore, we showed that the rate of
cognitive decline in a large cohort of HD patients was greater
in those possessing the H2 haplotype of the Tau gene
(microtubule-associated protein Tau (MAPT)) compared with
those with the H1 haplotype.22
It is thus becoming increasingly clear that HD is a tauopathy
at some level,19–23 although the molecular pathways involved
in this process remain largely obscure. In this respect, it is of
interest to note that activation of glycogen synthase kinase-3β
(GSK-3β) has a role in the phosphorylation of Tau (MAPT),
triggering cytoskeleton destabilization, Tau aggregation and
neuronal dysfunction/death.24–34 Furthermore, upregulation
of GSK-3β also promotes astroglial activation, astrocyte and
microglia migration and increased expression of proinflamma-
tory mediators,35–37 all of which may impair neuron–glial
interactions leading to exacerbation of neuronal vulnerability/
loss.38,39 As such, this signaling molecule may have a critical
role in mediating some of these Tau-related aspects of HD
pathology, especially given that several recent studies have
reported that GSK-3β signaling is dysregulated in cellular and
rodent models of HD and that GSK-3 inhibitors prevent cellular
polyQ toxicity caused by the HD mutation.40–45 However, no
clear consensus has emerged regarding whether GSK-3
activity is elevated or decreased in different HD-affected brain
regions.40–47 We thus sought to resolve this by studying one
affected brain region in HD, the hippocampus, in both TGmice
and human postmortem tissue, especially as very little is
known about GSK-3β transcription aswell as the kinase active
form of it, phosphorylated GSK-3 beta at Tyrosine 216
(pGSK-3β-Tyr216), which critically mediates neuronal–glial
dysfunction/death.27,31,33,38,39,48–52
Results
Tau pathology coincides with neuronal loss in the
hippocampus of HD patients. In accordance with recent
reports of Tau phosphorylation at the phospho-PHF-Tau
(AT8) epitope in the cortex and striatum of human HD
brains,23 we observed the presence of AT8 neuronal
inclusions in the granule cell layer (GCL) and hilus of HD
hippocampal sections but not of control (CT; Figures 1a–e).
Different morphologies of AT8-positive (AT8+) cells were
observed, including ring-like perinuclear, flame shaped and
globular morphologies, together with numerous neuropil
threads (Figures 1a–e), reminiscent of that observed in the
hippocampus of Alzheimer’s disease patients (Figure 1f).
These AT8+ neuronal inclusions were accompanied by a
progressive decrease in the number of cresyl violet-positive
(CV+) and microtubule-associated protein-positive (MAP2+)
neurons in the GCL of HD as compared with CT hippocampal
sections (Figures 1g and h), suggesting that pathological Tau
expression could contribute to the loss of neurons at this site
in HD patients.
Expression levels of GSK-3β and its kinase active form
pGSK-3β-Tyr216 are both increased in the human HD
hippocampus. Because GSK-3β can hyperphosphorylate
Tau (pTau) at the majority of its sites, including AT8,24–34 we
quantified GSK-3β levels in the HD and CT hippocampal
samples (Table 1)53 using quantitative PCR (qPCR). We first
analyzed the expression level and stability of 19 candidate
reference genes (Supplementary Table S1) by the geNorm,54
NormFinder55 and BestKeeper programmes,56 which ranked
RPL13A and RPLP0 as the most stable reference genes
(Supplementary Figure S1 and Supplementary Table S2). We
next validated the normalization accuracy of RPLP0 using the
quantification of glial fibrillary acidic protein (GFAP) gene
expression1,6,16 and supported expression which showed a
significant increase both at the mRNA and protein levels in
HD as compared with CT hippocampal samples (Supplemen-
tary Figure S3).
Using RPLP0 as a reference gene (Figure 2a), we then found
that GSK-3β mRNA transcripts were significantly increased in
the whole HD group (F=14.25; P=0.00063), as well as in the
separate HD Grades 2–4 relative to the CT cases, with the
Grade 4 group reaching the highest level of significance
(F=24.385; Po0.001) as compared with Grade 2 (F=5.775;
P=0.036) and Grade 3 (F=6.036; P=0.027) (Figure 2a).
We next investigated whether GSK-3β overexpression
observed in HD hippocampal samples was associated with
an increased expression of GSK-3β at the protein level
(Figures 2b–k). In CT hippocampi, GSK-3β co-localized
primarily with MAP2+ neurons in the GCL (Figures 2c and d)
and in pyramidal cells of Ammon’s horn (Figure 2e). MAP2,
a neuron-specific phosphoprotein and a substrate for
GSK-3β,28 was expressed at higher levels within the cell
bodies and dendrites in the CT brains, with the GSK-3β-IR
being preferentially distributed in the MAP2+ neuronal
cytoplasm with little staining in the nucleus (Figures 2c–e).
In HD cases, there was a significant increase of GSK-3β-IR
and of double-labeled MAP2+/GSK-3β+ neurons, which was
highest in Grade 3 brains (Po0.01, Figure 2b). As observed, a
strong GSK-3β-IR signal was detected in the MAP2+ neuronal
cytoplasm of GCL neurons (Figures 2f and g) and pyramidal
cells of Ammon’s horn (Figure 2h). MAP2 expression was
markedly reduced within the cell bodies and dendrites
of HD (Figures 2g and h) as compared with CT neurons
(Figures 2d and e). Double labeling with GFAP and GSK-3β
revealed GSK-3β expression in a restricted number of
astrocytes in CT (Figures 2i and j), whereas its expression
was detected in a much greater number of GFAP+ astrocytes
in HD (Figure 2k), showing a significantly increased (Po0.01)
GFAP-IR as well as cell density (Po0.01) in the dentate gyrus
(DG) as compared with CT (Supplementary Figures S3B–D).
The regulation of GSK-3β activity is brought about by complex
mechanisms, including phosphorylation.29,30,32–34,48–52 Here
we focused our analysis on pGSK-3β-Tyr216 as there is
substantial evidence that Tyr216 phosphorylation of GSK3β
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represents an important mechanism by which cellular insults
can lead to neuronal death27,31,33,38,39,48–50 and is known to be
stably expressed in the postmortem brains.57We found that, in
the CT hippocampus, faint pGSK-3β-Tyr216 labeling could be
observed mostly in the cytoplasm of MAP2+ neurons
(Figures 3c–e) while in HD there was a significant increase
(Po0.01; Po0.001) of the active kinase in MAP2+ neurons of
the DG, with the highest levels detected in Grade 3 HD
(Figures 3a, b and f–n). Furthermore, the distribution of
pGSK-3β-Tyr216 labeling in MAP2+ neurons was different in
HD compared with CT, with the pGSK-3β-Tyr216 staining being
primarily nuclear (Figures 3h, k and n). This was accompanied
by a decrease in the averageMAP2 fluorescence intensity (FI)
in GCL neurons at the level of the cell bodies and dendrites in
the HD samples (Figures 1g, j, 2g, h, 3d, g, j and m). Double
staining of pGSK-3β-Tyr216 with astroglial cell markers
indicated very little cytoplasmic/nuclear expression of the
active kinase in the DG and hilus of the CT hippocampus
(Figures 3o, r and s), whereas pGSK-3β-Tyr216-IR signal was
detected in greater numbers of HD hippocampal astrocytes
(Figures 3p–s). Again, the distribution of pGSK-3β-Tyr216
labeling in HD astrocytes was primarily nuclear (Figures 3p
and q). Taken together, these results show that GSK-3β gene
transcription is upregulated in the HD hippocampus and that,
at the protein level, GSK-3β and the active pGSK-3β-Tyr216
isoform are also increased both in neurons and astrocytes in a
stage-dependent manner in the HD GCL.
Active pGSK-3β-Tyr216 increases neuronal vulnerability
to oxidative stress in R6/2 TG mouse hippocampal
neurons. In order to expand on these findings, and given
the difficulty of studying causal links in disease pathways in
human postmortem tissue, we next turned to the well-
characterized R6/2 mouse model of HD.58 Using western
blotting, we first quantified the levels of active pGSK-3β-Tyr216
in hippocampal tissue from wild-type (WT) and TG mice
before (2.5–3 weeks) and after the onset of HD-like features
(48 weeks). We found a 3–4-fold increase of active
pGSK-3β-Tyr216 in premanifest and manifest mice
(Figures 4a–c) as has recently been reported in the R6/1
mouse model.47 In addition, GFAP and AT8 protein levels
were significantly increased in R6/2 mice as compared with
Figure 1 Hyperphosphorylated pathological Tau (AT8) expression coincides with the loss of MAP2-IR in the human HD hippocampus. Hippocampal slide series from HD
(n= 5 cases/severity Grade) and age- and sex-matched CT (n= 6) were studied. Immunofluorescent staining was carried out on serial paraffin-embedded hippocampal tissue
sections (6 μm in thickness). Cresyl violet staining was used to count the number of neurons present in the GCL. (a–e) Representative images of triple immunofluorescent
labeling (a and f) for MAP2+ neurons (in red) expressing phosphorylated Tau (AT8, in green) and DAPI (blue). Different morphologies of AT8+ cells, including ring-like perinuclear
(b, c, white arrow), flame (d, red arrow) and globular inclusions (b, red arrowhead) as well as neuropil threads (e) can be seen in the GCL and hilus of a Grade 3 HD patient and as
shown in the DG and hilus of an Alzheimer’s disease (AD) patient (f) for comparative purposes. (g–i) MAP2 and DAPI immunofluorescence in a CT (g), Grade 3 (h) and Grade 4 (i)
HD case with quantification (j and k) revealing a stage-dependent neuronal decrease in the DG. This result was further confirmed using a quantification of
cresyl violet-stained cells against a MAP2 labeling (k). Statistical analysis was performed by one-way analysis of variance with Newman–Keuls Multiple Comparison posthoc test.
Statistical differences (mean±S.D.) in panels (j and k) *Po0.05 versus CT; **Po0.01 versus CT. Scale bars in panels (a–e), (g–i)= 50 μm, (f)= 25 μm
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WT counterparts (Figures 4a–c). Consistently, astrocytic
pGSK-3β-Tyr216-IR was increased in the DG of TG, as
compared with that observed in WT mice (Figure 4d). This
pGSK-3β-Tyr216 increase was also seen in primary hippocam-
pal neuronal and astrocyte cell cultures derived from R6/2 mice,
when compared with active kinase levels detected in WT
counterparts (Figure 4e). In agreement with a previous study,21
phosphorylation of Tau at the AT8 epitope was not changed in
premanifest mice (Figures 4a–c), whereas a significant increase
was observed after the onset of the disease when compared
with WT mice, suggesting that mHtt can induce Tau hyperpho-
sphorylation with the progression of HD hippocampal pathology.
Accordingly, we next studied the impact of pGSK-3β-Tyr216
on neuronal viability in hippocampal neuronal cultures derived
from WT and TG mouse brains. Notably, unlike astrocytes,
neurons are highly vulnerable to mHtt in vitro13–18,40
(Supplementary Figure S4). Consistently, increased pGSK-
β-Tyr216 protein levels (Figures 4f and i) were associated with a
reduction in TG neuronal (TG-N) viability, as revealed by
decreased mitochondrial activity (Figure 4g), and increased
cell death (Figure 4h), as compared with TG astrocytes
(TG-A), which showed no change in cell viability as compared
with their WT counterparts (Supplementary Figure S4).
Because oxidative stress and mitochondrial dysfunction are
critically involved in HD,7,59 and given that GSK-3β becomes
activated when apoptotic cell death is initiated,27,38,39,48–50 we
addressed the contribution of GSK-3β hyperactivation to the
response of TG-N exposed to oxidative stress. A low dose of
hydrogen peroxide (H2O2) induced only a small increase in
pGSK-3β-Tyr216 in WT-N (Figures 4f and i) and a nearly
25% decrease in neuronal viability, as measured using
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT) reduction and lactate dehydrogenase (LDH) release
assays (Figures 4g and h). In contrast, exposure to the same
low oxidative challenge in TG neurons further increased the
upregulation in GSK-3β-Tyr216 protein levels (Figures 4f and i).
This was associated with an additional significant decrease of
TG-N (but not TG-A) viability as indicated by the sharp decrease
in mitochondrial activity and significant increase in cell death
markers (Figures 4g and h,Supplementary Figure S4). Finally,
pretreatment with the specific GSK-3β antagonist AR-AO14418
(N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea), AR)
rescued the TG-N neurons (Figures 4f–i).
TG astrocytes overexpressing pGSK-3β-Tyr216 lose their
neurotrophic and neuroprotective properties, exacerbat-
ing neuronal loss. Because GSK-3β upregulation may
impair astrocyte–neuron interactions,38,39 we next addressed
the effects of overexpressing GSK-3β using different
astrocyte–neuron co-culture paradigms and treatments
(Figure 5a). In both direct and indirect WT-N/WT-A
co-cultures, we confirmed the glial neurotrophic effects, as
revealed by increased MAP2 density and neurite length and
branching when compared with WT-N cultured without glia
(Figures 5b, d, n and o). In striking contrast to WT-A, in the
TG-N/TG-A co-culture paradigms, we observed a sharp
reduction of MAP2+ neurons, associated with reduced
neurite length and branching (Figures 5e and o) as compared
with WT-N/WT-A counterparts (Figures 5f and o), supporting
the concept that mHtt significantly impairs the neurotrophic
properties of astrocytes. Consistently, when TG-A mono-
layers were placed on top of WT-N, MAP2+ neuronal survival
was reduced as compared with WT-A/WT-N co-cultures
(Figures 5g and o), and conversely, when WT-A were layered
on top of TG-N, we observed a significant increase in MAP2+
neuronal survival (Figures 5e and o). This implies that mHtt
may induce specific astrocyte-derived factors/mechanisms,
which are at least in part responsible for reduced neuronal
survival. Remarkably, while exposure of WT-N/WT-A cultures
to low doses of H2O2 was without significant effects on
MAP2+ cell density (Figures 5j and o), a low oxidative H2O2
challenge in TG-N/TG-A co-cultures reduced the numbers of
MAP2+ neurons (Figures 5l and o), an effect that was even
more robust when compared with TG-N cultures alone
(Figures 5i, n and o), thereby supporting the contention that,
besides other neuronal effects, additional factors linked to the
TG-A exacerbate hippocampal TG-N vulnerability.
Depletion of neuronal GSK-3β attenuates Tau phosphor-
ylation and caspase3 activation in R6/2 neurons. GSK-3β
transgene expression induces Tau hyperphophorylation with
the formation of pretangle structures in the hippocampus, as
well as neuronal death, gliosis and learning deficits.25 We
thus addressed the specific role of neuronal versus astrocyte
Table 1 Characteristics of the human hippocampal samples
ID Grade Sex Age CAG allele1 CAG allele2
HD1 2 M 73 21 45
HD2 2 M 64 20 45
HD3 2 M 66 19 46
HD4 2 F 78 17 43
HD5 2 M 45 18 47
HD11 3 M 54 23 47
HD12 3 F 61 17 46
HD13 3 M 55 19 51
HD15 3 M 59 19 46
HD16 3 F 65 17 44
HD17 3 M 78 19 43
HD18 3 M 73 21 45
HD21 4 M 44 18 53
HD22 4 M 43 21 53
HD23 4 M 40 18 51
HD24 4 M 47 20 52
HD25 4 M 50 19 50
HD26 4 M 65 18 46
HD27 4 F 26 22 70
HD28 4 M 43 18 51
HD29 4 M 51 20 52
HD30 4 F 53 20 52
HD31 4 M 68 19 45
ID Sex Age
CT1 M 75
CT2 M 69
CT3 M 61
CT4 M 67
CT5 M 67
CT6 F 63
CT7 F 61
CT8 M 59
CT9 F 72
CT10 M 67
CT11 M 56
AD1 M 76
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GSK-3β by investigating the effects of a small interfering
(siRNA) against GSK-3β (siRNAGSK-3β)39,49,60,61 in either cell
type. The introduction of both a CT scrambled siRNA
(siRNACT) or siRNAGSK-3β was first tested in pilot experiments
by qPCR (Figure 6a) and western blotting (Supplementary
Figure S5). In WT-N transfected with the siRNACT, low dose
of H2O2 induced an approximately 25% decrease in neuronal
viability, which was associated with a small increase of
caspase3-like activity, whereas GSK-3β knockdown followed
by H2O2 treatment efficiently reversed caspase3 activation-
induced cell death (Figures 6b and c). In TG-N transfected
with a siRNACT and treated with PBS, AT8 protein levels were
significantly higher when compared with their WT counter-
part, whereas in GSK-3β-depleted TG-N, AT8 protein levels
were significantly decreased (Figures 6d and e). These
effects were associated with a decrease in DEVD-like
fluorescent signal in siRNAGSK-3β-transfected TG-N, as
opposed to TG-N treated with a scrambled siRNA
Figure 2 Upregulation of GSK-3βmRNA and protein levels in GCL neurons and astrocytes in the human HD hippocampus. (a and b) qPCR analysis of GSK-3β transcription
and immunoreactivity in CTand HD. The characteristics of the human hippocampal samples are described in Table 1. Statistical analyses were carried out between the total CT
and HD groups (n= 32) and across grade severity compared with the CT group. Statistical differences in mRNA expression levels (mean± S.D.) were determined using a one-
way analysis of variance followed by correction for multiple testing using the Tukey’s Multiple Comparison test; *Po0.05, **Po0.001; ***P= 0.0001. (b) Quantification of GSK-3β
FI and the percentage of MAP2+/GSK-β+ cells over the total number of MAP2+ neurons/field (means±S.D.), showing a significant increase of GSK-3β-IR and of double labeled
MAP2+/GSK-3β+ neurons, which was the highest in Grade 3 brains. *Po0.05 and **Po0.01 versus CT; #Po0.05 versus Grade 4. (c–h) Representative images of triple
labeling with MAP2 (red), GSK-3β (green) and DAPI (blue) depicting GSK-3β expression in the MAP2+ neurons in the granular and pyramidal cell layer both in a CT (c–e) and a
Grade 3 HD brain (f–h). (i–k) Triple labeling showing GSK-3β expression (red) in GFAP+ astrocytes (green) and DAPI (blue) in hippocampal sections from CTand HD (i–k). White
arrows (i, j) show a GSK-3β (red) expressing GFAP+ astrocyte (green) in the GCL of a representative control hippocampal section. Scale bars in panels (c), (f), (i), (k)= 50 μm;
(d), (e), (g), (h), (j)= 25 μm
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(Figure 6c), thereby suggesting that TG-N death is asso-
ciated with mHtt activation of pGSK-3β/pTau signaling
promoting caspase3 activation.
Depleting endogenous GSK-3β in TG astrocytes reverses
Tau phosphorylation and caspase3 activation. Next the
effect of GSK-3β depletion in TG astrocytes was addressed in
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the indirect co-culture paradigm. When TG-A were trans-
fected with a siRNACT and layered on top of TG-N, a sharp
loss of MAP2+ neurons was observed (Figure 6f), a decrease
that was magnified when compared with the decreased
MAP2+ neurons observed in TG-N alone. When cell death
was assessed by caspase3 activation, a greater increase
was detected in the TG-A/TG-N indirect co-cultures
(Figure 6g) or TG astrocyte-conditioned media (ACM)
paradigms (not shown) as compared with the TG-N alone,
further supporting astrocyte-induced exacerbation of cell
death. Interestingly, these effects were associated with a
sharp upregulation of AT8 protein levels (Figures 6h and i)
that was significantly greater as compared with TG-N without
glia (Figures 6d and e). By contrast, GSK-3β depletion in
TG-glia resulted in a significant reduction of caspase3
activation and AT8 upregulation in TG-N conditioned by
TG-A transfected with a siRNACT, together with a significant
enhancement of MAP2+ neuronal loss (Figures 6f–m). These
findings all suggest that the upregulation of GSK-3β in TG
astrocytes may drive a Tau phosphorylation-induced increase
in caspase3, thus exacerbating neuronal death in HD, at least
in part, via mHtt-expressing astrocytes.
Finally, we assessed the levels of the proinflammatory
cytokines, TNF-α and IL-6, and reactive nitrogen species
production and found significantly higher levels in TG-A
transfected with a siRNACT as compared with their WT
counterparts (Figure 7a). Especially, H2O2 induced additional
upregulation of the proinflammatory markers, and this was
significantly attenuated by the depletion of GSK-3β
(Figure 7a). Taken together, our findings show that active
GSK-3β is upregulated in the HD hippocampus, both in
neurons and astrocytes. This overactivation may potentiate
the cytotoxicity of mHtt both directly and indirectly through its
influence on astrocytes (Figure 7b).
Discussion
We first analyzed GSK-3β transcription as a function of
disease severity in HD postmortem hippocampal tissue and
found that its transcriptional dysregulation is a prominent
pathological feature of HD. Extensive immunohistochemistry
analyses corroborated our findings by showing increased
protein levels for GSK-3β and active pGSK-3β-Tyr216 in both
HD hippocampal neurons and astrocytes as a function of
disease severity. Coincident with this pathology, we also found
phosphorylation of Tau at the AT8 epitope, as well as a decline
in CV+/MAP2+ neurons in the DG of HD patients.
We then confirmed these findings in a well-recognized
(R6/2) HD mouse model, recently shown to develop Tau
hyperphosphorylation at multiple Tau phosphoepitopes
(AT8, CP13, PT205 and PHF-1) following the onset of HD-like
features.21 We found an upregulation of both pGSK-3β-Tyr216
and GFAP protein levels in the hippocampus of premanifest
R6/2 mice that increased with disease progression. This
suggests that mHtt may activate GSK-3β both at an early stage
of the disease process as well as throughout the disease
course. Thus we chose to explore this further in vitro with
experiments, which revealed that there is an upregulation of
pGSK-3β-Tyr216 in both primary neurons and astrocytes
harvested from the R6/2 mouse brain as well as decreased
R6/2 neuronal viability. This, we hypothesized, could be due to
an elevated level of oxidative stress. To confirm this, we
mimicked such a state by challenging TG-N with a moderate
oxidative stimulus and by using a specific GSK-3β antagonist
as well as genetic depletion of GSK-3β, and we were able
to causally link active GSK-3β to mHtt-induced increased
AT8 accumulation, caspase3 activation and R6/2 neuronal cell
loss. To further dissect the potential role of R6/2 astrocytes in
this process, we used different co-culture paradigms between
WT/TG astrocytes and WT/TG neurons. This revealed that
TG-A overexpressing GSK-3β lose their neurotrophic and
neuroprotective properties and thus fail to protect and support
eitherWTor TG hippocampal neurons, via, in part, the aberrant
production of proinflammatory mediators. Furthermore, deple-
tion of GSK-3β in R6/2 astrocytes showed that mHtt-induced
GSK-3β overexpression in this cell type is also a crucial factor
driving AT8 accumulation, caspase3 activation and reduced
neuronal survival. All of this suggests that GSK-3β over-
activation may potentiate mHtt neurotoxic effects both directly
and indirectly through an influence on astrocytes (Figure 7b).
Converging evidence implicates GSK-3β as a key signaling
molecule involved in the maintenance and function of adult
neurons.25–33,38–40,43–45,48–50,59 In particular, GSK-3β activa-
tion has a central role in regulating the neuroinflammatory and
astroglial response to neurodegeneration.35–39 There is also
mounting evidence to show that mHtt impairs astrocyte
properties and that this may have an important role in the
pathology of HD.5,13–18 Taken together, these findings suggest
that GSK-3β dysregulation in both neurons and glia represents
a crucial vulnerability factor and a potential target for mitigating
the progression of pathology in HD hippocampus.
A special feature of GSK-β in neurodegenerative diseases
is the phosphorylation of the protein Tau, which is detrimental
to neurons. Recently, pathological Tau aggregates have been
Figure 3 Increased expression and translocation of the GSK-3β-Tyr216 isoform in human HD hippocampus. (a) pGSK-3β-Tyr216 immunofluorescence intensity and (b) the
number of MAP2+ cells expressing pGSK-3β-Tyr216 in HD versus CT (n= 16). Statistical differences were determined by a one-way analysis of variance (ANOVA) with Newman–
Keuls Multiple Comparison posthoc test. **Po0.01 versus CT; ***Po0.001 versus CT; #Po0.05 versusGrade 4. Note the sharp increase of MAP2+ cells expressing pGSK-3β-
Tyr216 in Grades 2–4 HD versus CT (b), with the highest level of pGSK-3β-Tyr216-IR being detected in Grade 3 HD (a). (c–n) Representative images depicting triple
immunofluorescent labeling of neurons for MAP2 (red), pGSK-3β-Tyr216 (green) and DAPI (blue) in a (c–e) CT, (f–h) Grade 2, (i–k) Grade 3 and (l− n) Grade 4 HD brain.
p-GSK-3βTyr216 expression in MAP2+ neurons have a preferential nuclear distribution in HD cases (f–n), whereas in CT faint immunoreactivity is located within the cytoplasm
(c–e). (o–q) Triple immunofluorescent staining of pGSK-3β-Tyr216 (in red), GFAP (in green) and DAPI (blue) revealed scarce cytoplasmic or nuclear expression of the active
kinase in the majority of astrocytes in the DG and hilus of CT subjects (o). In HD, both pGSK-3β-Tyr216-negative and pGSK-3β-Tyr216-positive astrocytes were observed in the DG
and hilus (p and q). (r and s) The number of astrocytes was greater in the HD hippocampi as compared with CTas well as the level of pGSK-3β-Tyr216 expression. Statistical
differences were determined by a one-way ANOVA with Newman–Keuls Multiple Comparison posthoc test. *Po0.05 versus CT; **Po0.01 versus CT; ***Po0.001 versus CT.
Changes in the percentage of double-labeled GFAP+/GSK-3β+ cells over the total number of GFAP+ cells/field in DG areas (means± S.D.) showed that only a limited number of
GFAP+ cells expressed GSK-3β in CT brains, whereas there was a significant increase (**Po0.01 versus CT) of double-labeled astrocytes in HD (o–q). SGZ, subgranular zone
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Figure 4 Contribution of active pGSK-3β-Tyr216 to mHtt-induced neuronal death in R6/2 hippocampus. (a–c) Hippocampi were analyzed from WTand TG mice at 3 weeks
(premanifest, n= 6 each for TG and WT) and at≥ 8 weeks (manifest, n= 6 each for TG and WT). Quantification of phosphoepitopes was performed versus total GSK-3β or total
Tau, respectively, and normalized to β-tubulin. GFAP quantification was performed versus β-tubulin (as loading control). Results are expressed as the percentage of WT mice.
Data are mean±S.D. Statistical differences were analyzed by analysis of variance followed by a Newman–Keuls test. **Po0.01 versus WT. (b and c) Two continuous lanes
(side by side) from the same blot are displayed for each condition. Black borders correspond to where the images were cropped. (d) Representative immunofluorescent staining of
hippocampal sections from 12-week-old WT and R6/2 mice showing increased pGSK-3β-Tyr216-IR in the DG of HD mice, whereas only a faint staining is observed in the WT
counterparts. Triple immunofluorescent staining with DAPI (blue), GFAP (green) and pGSK-3β-Tyr216 (red) shows increased staining of the active kinase, which co-localizes with
TG but not WTastrocytes. (e) WTand TG mice brains showing increased pGSK-3β-Tyr216 in TG as compared with WT cells and western blotting analysis of pGSK-3β-Tyr216 in
primary hippocampal neurons and astrocytes showing increased pGSK-3β-Tyr216 in TG as compared with WT cells. Two representative lanes for neuronal (WT-N, TG-N) and
astrocyte (WT-A, TG-A) cells are displayed. *Po0.05 versus WT. (f and i) Western blotting analyses of pGSK-3β-Tyr216 levels in hippocampal neurons at 7–10 DIV after a mild
oxidative stress challenge (H2O2, 0.5 μM) in WTand TG cultures, with or without pretreatment (−1 h) with the specific GSK-3β antagonist AR (5 μM).70,73 Two representative
continuous lanes are displayed (−AR and +AR) for WT and TG cells, both in PBS- and H2O2-treated conditions. *Po0.05 versus PBS in WT and TG cultures, respectively;
○Po0.01 versusWT cultures; #Po0.05 versus H2O2. (g and h): MTTreduction assay and LDH release under basal conditions (PBS) and after a mild oxidative stress challenge
(H2O2, 0.5 μM) in WTand TG cultures, in the absence or not of (−1 h) AR (5 μM). Values are expressed relative to untreated WT cells (percentage of WT) and represent the
mean± S.D. of four replicates. *Po0.05 versus PBS in WT and TG cultures, respectively; ○Po0.01 versus WT cultures; #Po0.05 versus H2O2. A, astrocytes; N, neurons
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seen in cortical and striatal HD tissue,22,23 and while our new
study did not specifically address this aspect of HD pathogen-
esis, we did observe AT8 neuronal inclusions in the GCL and
hilus of Grades 2–3 hippocampal sections fromHD patients. In
animal models of HD, Gratuze et al.,21 have also recently
reported that there is extensive phosphorylation of Tau in the
hippocampus, cortex and striatum of R6/2 and 140 CAG
knock-inmice, subsequent to the onset of HD pathology,21 and
the present study corroborates this by showing increased AT8
protein levels in the R6/2 hippocampus. The critical role of
Figure 5 Impaired glial neurotrophic and neuroprotective properties by hyperactive pGSK-3β-Tyr216 in R6/2 astrocytes. (a) Schematic drawing showing the co-culture
experiments. In the direct co-culture paradigm, WT/TG neurons were layered on top of WT/TG astrocytes for 7–10 DIV, allowing contact between neurons and astrocytes. In the
indirect co-culture, glial inserts were added on top of the purified neurons, allowing only factor diffusion. (b, c, h, i) Representative images of MAP2+ staining in WT-N and TG-N
cultured alone or in the presence (or not) of mild oxidative stress (H2O2, 0.5 μM). (d–g), (j–m) Double immunofluorescent staining with GFAP and MAP2 in the direct co-culture
paradigms in the absence (d–g) or presence (j–m) of a mild oxidative stress (H2O2, 0.5 μM). (n and o) Neuronal survival as determined by MAP2
+ cell counting in the different
conditions. Values are expressed as the percentage of WT and represent the mean± S.D. of four replicate counts in each condition. Statistical differences were analyzed by
analysis of variance followed by a Newman–Keuls test *Po0.05 versus PBS in WTand TG cultures, respectively; ○Po0.01 versusWT cultures; **Po0.01 versusWT-A/WT-N;
#Po0.01 versus TG-A/TG-N. A, astrocytes; E18, embryonic day 18; N, neurons; P-2, postnatal day 2
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dysregulated endogenous GSK-3β in this process was further
documented in GSK-3β-depletion experiments, where
GSK-3β knockdown in TG-N significantly attenuated cas-
pase3 activation and AT8 accumulation. Moreover, we show
that there is an additional contribution to this cell loss from
changes in GSK-3β in mHtt-containing astrocytes, supporting
astrocyte–neuron interactions as essential components in the
neuronal dysfunction that characterises neurodegenerative
diseases, including HD.5,13–18,38,39,62–65
This enhanced GSK-3β activation in TG-A not only
impaired their neurotrophic and neuroprotective properties
but also significantly contributed to mHtt-induced
Tau phosphorylation and caspase3 activation, possibly
via an exacerbated production of major proinflammatory
mediators (Figure 7), as recently highlighted in the study of
Garwood et al.64 indicating that astrocytes are important
for Aβ-induced Tau phosphorylation, caspase3 activation and
cell death.64
Figure 6 Synergistic effect of neuronal and astrocyte hyperactive GSK-3β in the exacerbation of Tau phosphorylation and neuronal death in R6/2 hippocampal cultures.
(a) qPCR quantification of GSK-3βmRNA following a treatment with siRNAGSK-3β or a siRNACT in neurons. Po0.05 versus siRNACT within TG-N and TG-A, respectively. (b) Cell
viability in the presence of a mild oxidative stress, siRNAGSK-3β, siRNACT or PBS was measured with the MTTreduction assay. (c) Caspase3 activity was also measured using the
fluorogenic substrate DEVD-AFC. (d and e) Tau phosphorylation at the AT8 epitope was determined by western blotting and quantifications performed against total Tau. Two
representative continuous lanes are displayed (siRNACT and siRNAGSK-3β) for WTand TG, both in PBS- and H2O2-treated conditions. Values are expressed as a percentage of
WT cells and represent the mean±S.D. of four replicate counts in each condition. Statistical differences were analyzed by analysis of variance followed by a Newman–Keuls test.
*Po0.05 versus siRNACT-PBS-treated cells, within WT and TG cultures, respectively; ○Po0.01 versus WT cultures; *Po0.05 versus siRNACT-H2O2-treated cells.
(f–i) Quantification of neuronal survival (f), caspase3 activity (g) as well as Tau phosphorylation at the AT8 epitope (h) following GSK-3β silencing in TG astrocytes using the
indirect co-culture (TG-A/TG-N) paradigm with or without mild oxidative stress. Values are expressed as a percentage of WT cells and represent the mean± S.D. of three
replicate counts in each condition. *Po0.05 versus PBS-treated cells; **Po0.01 versus siRNACT cultures. (j–m) Representative images of MAP2+ fluorescent staining of
TG-N neurons in the presence of an H2O2 challenge when cultured alone (j and k) or with TG-A (l and m)
GSK-3β disruption of glia–neuron crosstalk in HD
F L’Episcopo et al
10
Cell Death and Disease
In conclusion, we have shown that there is mHtt-induced
GSK-3β dysregulation in both neurons and astrocytes of the
hippocampus in HD has a crucial role in the evolving pathology
seen in this disorder. This may not only explain the selective
vulnerability of this structure to the disease process and its clinical
expression but also open up new therapeutic avenues bywhich to
slow down or even reverse this currently incurable condition.
Materials and Methods
Study design. The aim of the postmortem work was twofold: (i) to investigate
the expression and impact of GSK-3β and its active pGSK-3β-Tyr216 isoform in the
HD hippocampus at different stages of disease; and (ii) to identify reliable
endogenous candidate reference genes for normalization of qPCR targeted gene
expression in human HD hippocampal tissue. The study was approved by the
Ethical Research Committee of the Centre Hospitalier Universitaire de Québec
(#A13-02-1138) and the OASI Institute for Research and Care on Mental
Retardation and Brain Aging (Troina, EN, Italy) ethical board following the guidelines
of the Declaration of Helsinki. Human brain tissues were obtained from the
Cambridge Brain Bank and used under full ethical approval (REC 01/177).
Postmortem samples. HD cases (CAG435) ranged from 43 to 78 years of
age (56.8± 12) years (Table 1). All diagnoses were based on genetic confirmation
of the expanded CAG repeat (see Table 1) along with clinical history and
histopathological evaluation by an experienced neuropathologist using the Vonsattel
classification.53 Sample distribution included Grade 2 (n= 5), Grade 3 (n= 7) and
Grade 4 (n= 10) tissues; the mean sizes of the longer and shorter CAG repeats
were 48.0± 5.5 and 19.0± 1.4, respectively. The postmortem interval (PMI) was
25.7± 12.4 h and brain acidity–alkalinity (pH) values were 6.54± 0.3. CT samples
(n= 11) were neurologically normal cases, matched for age (65.1± 14 years), PMI
(26.4± 9.9 h) and pH values (6.49± 0.38). Fresh frozen dissected hippocampi
were used for RNA isolation while paraffin-embedded sections were used for
immunofluorescence analyses.
Human reference gene panel. A variety of factors affect reference gene
mRNA in postmortem human and rodent brain tissues and a careful and stringent
selection of a proper constitutively expressed CT gene prior to qPCR analysis is
therefore essential.54–56,66 We thus analyzed 19 candidate genes (Human
Reference Gene Panel, Roche Applied Bioscience, Penzberg, Germany, http://
www.roche-applied-science.com) from different abundance and functional classes,
derived from literature searches and as presented in Supplementary Table S1.
RNA isolation, cDNA synthesis and qPCR assays. The human
hippocampus was dissected (approximately 50 mg) using a cryostat and collected
for RNA extraction using an RNeasy Lipid Tissue Mini Kit (Qiagen, Toronto, Ontario,
Canada) and RNA extraction procedure carried out as described.67 Briefly,
hippocampal tissue was homogenized in 1 ml of trizol, followed by the addition of
200 μl of chloroform. The homogenate was subsequently separated into aqueous
and organic phases by centrifugation and ethanol was added to the aqueous phase
before being passed through an RNeasy column. RNA was eluted in 30 μl of
RNAse-free water. The purity of the RNA was determined by measuring the
absorbance A260/A280 in a buffered solution at pH 7.4 using nanodrop. The quality
and integrity of the extracted RNA was assayed by agarose gel electrophoresis to
detect the presence of ribosomal RNA degradation.67 One μg of RNA was taken for
synthesis of complementary DNA (cDNA) using a cDNA Synthesis Kit (Life
Technologies Europe BV, Monza, Italy, www.lifetechnologies.com) according to the
manufacturer’s guidelines. The qPCR was carried out as described38,39,60,61
(Supplementary Experimental Procedures), using 50 ng of cDNA and according to
the manufacturer’s protocol (http://www.roche-applied-science.com).
Gene analysis and statistics. To compare gene expression stability and
rank, geNorm,54 NormFinder55 and BestKeeper56 algorithms were used as detailed
in Supplementary Methods. To maximize power, analyses were applied to three
groups: (i) all HD cases combined with the neurologically normal cases (CT) as a
single group (A); (ii) the HD group alone (B) and (iii) the CT group alone (C). Non-
paired Student’s t-tests were used to determine whether the CT and HD groups
differed on individual reference genes or geomean. To compare the homogeneity
of the qPCR values of the 33 samples, we performed a two-sided Grubbs’ test
(at significance level P≤ 0.01) for each gene. Correlations among continuous
variables were performed to determine whether any of the studied variables related
to housekeeper/target gene mRNA levels or their geometric means. Statistical
significance level was set at P≤ 0.05.
Target gene studies. After combinatorial analyses for the selection of a
suitable reference gene and validation by comparison with less suitable ones (PPIA,
S18) using quantification of the GFAP gene, we addressed changes in mRNA levels
of GSK-3β using RPLP0 as the internal CT gene (Supplementary Figure S3).
We used a duplicate assay for each sample. GSK-3β (ID: Hs01047719-m1), GFAP
(ID: Hs00909233-ml), RPLP0 (ID:4326314E), PPIA (ID: 4326316E) and S18
(ID: 4319413E) were obtained from Applied Biosystems (Life Technologies).
Quantification of the abundance of target gene expression was determined relative
Figure 7 GSK-3β depletion counteracts cytokine overproduction of R6/2
astrocyte. (a) Astrocytes transfected with either a siRNACT or siRNAGSK-3β were
treated (dashed lines) or not with H2O2 (0.5 μM) for 48 h. Levels of TNF-α and IL-6 in
the medium were determined using an ELISA.68,70 The level of NO in the medium
was determined with the Griess reagent.68,70 Data are presented as the mean±S.E.
of three independent experiments. Statistical analysis was performed by one-way
analysis of variance with Newman–Keuls Multiple Comparison posthoc test;
*Po0.05 versus PBS within WT-A and TG-A cultures, #Po0.01 versus WT;
○Po0.01 versus siRNAGSK-3β within WT and TG astrocytes, respectively.
(b) Astrocytes hyperexpressing GSK-3β drive Tau phosphorylation and caspase3
activation-induced cell death. Schematic drawing illustrating potential interactions of
GSK-3β in mHtt-induced neuronal toxicity. mHtt-associated GSK-3β overactivation in
hippocampal neurons may increase neuron vulnerability, promoting MAP2 instability
and accumulation of pTau. Abnormal activation of GSK-3β in HD astrocytes
may inhibit their neuroprotective functions and progressively exacerbates
inflammation.34–39,65 All together and in synergy with mHtt-associated neuronal
and astrocyte impairments, these effects may further magnify pTau accumulation
leading to caspase3-dependent neuronal dysfunction/death
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to the reference gene with respect to the CT group by using the delta delta Ct (2−ΔΔCt)
comparative method. Statistical analysis of variance used a one-way ANOVA, followed
by correction for multiple testing using the Tukey’s Multiple Comparison test.
Immunofluorescence and microscopy analyses. Hippocampal slide
series of HD (n= 16) as well as age- and sex-matched CT (n= 10) cases were
studied. Immunofluorescent staining was carried out on serial paraffin-embedded
hippocampal tissue sections (6 μm in thickness). Adjacent sections were stained with
CV acetate (0.1 w/v) to count the number of neurons present in the GCL in each
section.38,39 Immunostaining was carried out as described previously.60,61,67–69 Briefly,
after deparaffinization, antigen retrieval was performed by incubating the sections in
citrate buffer 10 nM pH 6 at 95 °C for 30 min. The sections were subsequently
washed three times in PBS at room temperature (RT). To reduce signal interference
from tissue autofluorescence, all sections were incubated with Sudan Black B
(Harleco, Philadelphia, PA, USA), 0.5% in 70% alcohol, for 5 min. Sections were
washed in PBS containing 0.2% Triton X-100 (3 × 10 min) between each step. Primary
and secondary antibodies (Abs; Supplementary Table S4) were diluted in a blocking
buffer of 5% normal serum, 5% bovine serum albumin and 0.4% Triton X-100 in PBS.
After overnight incubation with the primary Abs, the sections were rinsed and
incubated in darkness for 2 h with CY3/FITC-conjugated donkey anti-rat, donkey anti-
rabbit, donkey anti-mouse and donkey anti-goat antibodies (1 : 200–400; Jackson
ImmunoResearch, Suffulk, Europe LTD, UK), mounted on glass slides and
coverslipped with glycerol-based mounting medium. All Abs used in this study have
been previously tested and validated for immunofluorescence and western
blotting.38,39,60–62,70 Nuclei were counterstained with 4′,6-diamino-2-phenylindole
(DAPI) in mounting medium, (H1200) Vector Laboratory, Burlingame, CA, USA.
Slides where the primary antibody was omitted served as a negative CT to ensure
that there was no autofluorescence from the secondary antibody in the reaction
sequence of the labeling experiments. Immunostaining was examined using an
Olympus fluorescent microscope BX-51 (Segrate, Milan, Italy) and a Leica TCS-SPE
confocal microscope (Leica Lasertechnik GmBH, Heidelberg, Germany).
Confocal laser scanning microscopy, image analysis and quanti-
fication of immunostaining. All assessments were performed by a blinded
observer. For fluorescent microscopy of hippocampal sections, images were obtained
using an inverted Leica LCS-SPE confocal microscope (Leica Lasertechnik GmBH)
equipped with an argon/krypton laser or a Fluoroview FV1000 confocal microscope
(Olympus Canada Inc., Richmond Hill, Ontario, Canada). For FI assessments and
co-localizations, hippocampal sections were labeled by immunofluorescence, and
images were acquired by sequential scanning of 12–16 serial optical sections. 3D
reconstructions from z-series were used to verify co-localization in the x–y, y–z and
x–z planes. To estimate cellular pGSK-3β/-Tyr216 fluorescence in the DG, the cell
fluorescence was acquired separately with the FITC and CY3 filters, as detailed
elsewhere.60,69 For cell counting, serial fluorescent images were captured in randomly
selected areas along the DG and the number of labeled cells per field (14–18 fields/
section) was manually counted in three to four hippocampal sections/case, using the
Olympus cellSense Dimension software (Segrate , Milan, Italy), and results expressed
as mean±S.D.
Studies in R6/2 mice. R6/2 mice, TG for exon 1 of the human Htt gene58 and
WT littermates were initially obtained from the Jackson Laboratory (Bar Harbor, ME,
USA) and mated with female CT mice (B6CBAFI/J). Offspring were verified by a
PCR genotyping technique using DNA extracted from tail tissues using primers
(5′-CCGCTCAGGTTCTGCTTTTA-3′ and 5′-GGCTGAGGAAGCTGAGGAG-3′)
located in the transgene. The study was carried out in premanifest (3 weeks of
age) and manifest mice (48 weeks of age) as the onset of HD features in these
mice occurs at 8 weeks of age.58 The tail test was used to detect the abnormal
clasping of the hind limbs and was employed to ensure the premanifest status of the
R6/2 mice.58 Mice were suspended by the tail for 10 s; if the mouse acquired a
locked body position, the result was scored as positive. The animals were weighed
once a week and handled according to National Institutes of Health guidelines. The
protocol received approval by the institutional Animal Care and Use Committee, and
all studies were conducted in accordance with the United States Public Health
Service's Policy on Humane Care and Use of Laboratory Animals.
Primary neuronal cell cultures. Primary cultures of hippocampal neurons
were generated from TG R6/2 and WT mice. Briefly, at embryonic day 17, tails from
each embryo were used to extract genomic DNA and to perform PCR for genotype
determination. The brains were next removed and hippocampi were dissected free of
meninges in Ca2+/Mg2+-free Hanks’ balanced salt solution (HBSS) and rinsed twice
with HBSS allowing the tissue to settle to the bottom of the tube. After the second
wash, the tissue was resuspended in HBSS containing 0.25% (w/v) trypsin (without
phenol red) and incubated for 15 min at 37 °C. After three rinses with HBSS, the tissue
was mechanically dissociated in plating medium (Dulbecco’s modified Eagle’s medium,
GIBCO, Rockville, MD, USA), supplemented with 10% horse serum (GIBCO),
100 U/ml penicillin and 100 mg/ml streptomycin by gentle passage through Pasteur
pipettes. Dissociated hippocampal cells were seeded in poly-L-lysine-coated six-well
culture plates at a density of 7 × 105 cells per well in plating medium. Cultures were
maintained at 37 °C in 5% CO2 for 2 h before the plating medium was replaced with
neurobasal growth medium (GIBCO) supplemented with B27 (GIBCO), 2 mM
L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. At day 2, cultured
neurons were treated with 1-β-D-arabinofuranosylcytosine 2 μM for 24 h.38,39 The
medium was changed every 3 days, and after 7–10 days in culture (days in vitro (DIV)),
cells were used for the experiments. The purity of the neuronal cultures (≥95%) was
determined by immunofluorescence staining for the neuron-specific marker, MAP2.
Primary astrocyte cultures. Primary astrocyte cell cultures were obtained
from mouse hippocampi of postnatal 2–3-day-old WT and TG mice, as described
previously.38,39,60,61,69,71 The cultures were allowed to grow and differentiate until they
reached confluency at which time (21–25 DIV) the loosely adherent microglial cells
were separated by shaking for 2 h at 37 °C and 190 r.p.m. The attached cells were
then washed with sterile PBS and incubated for 1–2 h at 37 °C incubator, at 5% CO2,
before overnight shaking at 37 °C and 210 r.p.m. The supernatant media containing
oligodendrocyte precursors and other cell types were discarded. The glial (495% of
the cells were GFAP-IR astrocytes) monolayers were then rinsed with sterile PBS and
replated at a final density of 0.4–0.6 × 105 cells/cm2 in poly-D-lysine (10 μg/ml)-coated
6, 12- or 24-well plates or in insert membranes (0.4 μm polyethylene terephthalate) for
indirect co-culture (BD Biosciences, Becton Dickinson Labware, Franklin Lakes, NJ,
USA). Astrocyte monolayers were used for direct or indirect co-cultures or processed
for gene silencing and used for indirect co-cultures with primary hippocampal neurons,
as described. Alternatively, the neuronal cultures were exposed to the ACM.69
Preliminary dose–response and time course pilot experiments on neuronal and
astrocyte cell viability of WT and TG cultures were first carried out using a range of
concentrations of H2O2 (0.25–25 μM) and a concentration range of 0.5 μM was
selected for the study. Consistent with earlier and more recent reports on primary
cortical and striatal R6/2 cultures, we detected an increased vulnerability of
hippocampal R6/2 neurons, while the viability of R6/2 astrocytes was not affected by
such stressors13,17,18,40 (Supplementary Figure S4). Both purified neuronal cultures
and astroglial–neuronal co-cultures at 8–9 DIV received PBS or H2O2 (0.5 μM).
Pharmacological antagonism of GSK-3β was carried out with the specific GSK-3β
antagonist, AR (of 5 μM)38,39,71 administrated for 60 min before H2O2. Viability
assays, caspase3 activity and protein extracts for western blotting determinations of
protein levels were carried out as part of these neuronal cultures; other neuronal
cultures were used for immunocytochemistry and cell counting. Briefly, the cultures
were fixed in 4% paraformaldehyde in PBS and processed using immunofluorescent
staining procedures,38,39,52,53 employing anti-MAP2 and anti-GFAP, as described
above. Nuclei were counterstained with DAPI. Analyses were performed using a
confocal laser microscope and computer-assisted image analysis (Leica). For
quantification of the amount of cells expressing a given marker or marker combinations,
the number of MAP2+ cells was determined relative to the total number of DAPI-labeled
nuclei, using the Leica lite Software (Leica, Heidelberg, Germany) and three-
dimensional overlay to avoid false-positive/negative overlay and double counting.
Cell viability and caspase3 activity assays. Primary neuronal and
astrocyte cell cultures treated as above were analyzed for membrane integrity by
exclusion of Trypan blue (0.12% wt/vol), metabolic reductase activity using the MTT
assay and cell death by the LDH release and caspase3 assay.38,39,60,61,69 For the
MTT assay, MTT was added to the existing culture medium (final concentration of
120 μM) for 15 min after which the media was removed. Reduced MTT solubilized
with 200 μl DMSO was then measured by absorbance at 585 nm. The LDH assay
used the LDH Cytotoxicity Detection Kit (Roche) as per the manufacturer’s
instructions. For caspase3 activity measurements, the cells were lysed in ice-cold
lysis buffer and processed as detailed elsewhere.38,39,60,61,69 The fluorogenic
substrate DEVD-AFC (15 μM; Calbiochem System Products, San Diego, CA, USA),
used for quantification of DEVD-like fluorescent signal, was assessed using
a luminescence spectrophotometer (Beckman Coulter, Cassina de’ Pecchi, Milan,
Italy) (excitation 400 nm and emission 505 nm). Enzymatic activity (arbitrary
fluorescent units) is expressed as the percentage of CTs.
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Transient gene silencing with siRNA. To test the effect of GSK-3β
protein depletion, we used targeted mRNA degradation using siRNA performed as
described previously.39,49,60,61 GSK-3β siRNA (sc-35525) and CT siRNA (sc-37007)
were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). siRNA
introduction was performed according to the protocol provided by Santa Cruz
Biotechnology, as reported in detail in our previous studies.39,60,61 Briefly, to prepare
lipid–siRNA complexes, 80 pmol of the indicated siRNA duplex in 100 μl of
Transfection medium (sc-36868) and 6 μl of siRNA Transfection reagent (sc-29528)
in 100 μl of Transfection medium were combined, incubated for 30 min at 25 °C and
diluted with 800 μl of prewarmed Transfection medium. The cells were dissociated
and plated on 24 plate cells in growth medium, rinsed once with serum-free
DMEM and 1000 μl of lipid–siRNA mixture (as described above) was applied to
each well. After incubation for 6 h at 37 °C in a humidified 5% CO2 cell culture
chamber, an additional 1 ml of 20% FBS in DMEM was added to each well, and
lipofection was allowed to continue overnight. The next morning, the lipofection
medium was aspirated, and transfected cells were re-fed with fresh growth medium.
The cells were collected 72 h after transfection for qPCR and western blotting
assays.
Protein extraction and western blotting. For hippocampal tissues, mice
were killed by decapitation and the brains immediately removed and the tissues
dissected on ice, then frozen on dry ice and kept at − 80 °C until studied. Dissected
hippocampi were homogenized and processed, as described previously38,39
(Supplementary Methods), proteins quantified using the BCA protein determination
method (Bio-Rad, Hercules, CA, USA). SDS-PAGE and western blotting analysis of
hippocampal samples/cell homogenates were then performed as detailed in
L’Episcopo et al.61 and Tunbridge et al.66 Briefly, hippocampal tissue or cell
homogenates were separated on SDS-10% polyacrylamide gel and then transferred
onto nitrocellulose membranes (Amersham Biosciences, Pittsburgh, PA, USA). Non-
specific binding sites were blocked with 5% non-fat dry milk in phosphate-buffered
saline containing 0.1% Tween 20 (PBS-T) for 1 h at RT and were afterwards
incubated overnight at 4 °C with the specific antibodies (Supplementary Table S4).
The following day, membranes were washed three times in PBS-T and then
incubated for 1 h at RT with the corresponding HRP-conjugated secondary
antibodies in 5% non-fat dry milk in PBS-T, and the immunoreactive signal intensity
was visualized by enhanced chemiluminescence (ECL Plus, GE Healthcare
Biosciences, Piscataway, NJ, USA). Immunoreactive bands were visualized using
the ImageQuant LAS 4000 imaging system (Fujifilm USA, Valhalla, NY, USA).
Quantification of phosphoepitopes was performed relative to their non-
phosphorylated proteins and was normalized to β-tubulin or β-actin as loading
controls. Results are expressed as the percentage of WT mice. Data are mean±
S.D. with n= 6 for each condition.
Enzyme-linked immunosorbent assay (ELISA) and NO produc-
tion. Levels of cytokines were determined using the ELISA kits (DuoSet ELISA
Development System, R&D Systems, McKinley Place, MN, USA) following the
manufacturer’s protocol.60,72 NO production was determined by measuring the
accumulated levels of nitrite in the culture supernatants with the Griess reagent.61,72
Statistical analyses. Results for immunocytochemistry, immunoblots, in vitro
viability and caspase3 assays, GSK-3β depletion experiments and ELISA assays
are expressed as mean± S.D. unless otherwise noted. Statistical analysis was
performed by one-way ANOVA with Newman–Keuls Multiple Comparison posthoc
test. Statistical significance was accepted at Po0.05.
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